Kiniksa Pharma Reports Director/Officer Changes & Compensatory Info
Ticker: KNSA · Form: 8-K · Filed: Apr 23, 2025 · CIK: 1730430
| Field | Detail |
|---|---|
| Company | Kiniksa Pharmaceuticals International, PLC (KNSA) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
TL;DR
Kiniksa Pharma filed an 8-K detailing director/officer changes and compensation plans.
AI Summary
Kiniksa Pharmaceuticals International, plc filed an 8-K on April 23, 2025, reporting events as of April 17, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance and executive compensation matters, which typically carry low immediate risk.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Registrant
- April 17, 2025 (date) — Earliest event date
- April 23, 2025 (date) — Filing date
FAQ
What specific director or officer positions were affected by the reported changes?
The filing indicates the departure of directors or certain officers and the election/appointment of new ones, but does not specify names or exact positions in the provided text.
Are there any details on the compensatory arrangements for the officers mentioned?
The filing states that compensatory arrangements of certain officers are part of the report, but specific details are not included in the provided excerpt.
What is the significance of the 'Financial Statements and Exhibits' item in this 8-K?
This indicates that financial statements and other relevant exhibits are being filed alongside the report on director/officer changes and compensation.
When was Kiniksa Pharmaceuticals International, plc incorporated or organized?
The company was incorporated or organized in England and Wales.
What is the primary business of Kiniksa Pharmaceuticals International, plc?
The company operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).